GSK Pharmaceuticals India Q4 FY25 Earnings Results: Profit Jumps 35% on Strong Vaccine Sales

GlaxoSmithKline Pharmaceuticals India (GSK), the Indian arm of UK-based GSK, has posted a 35% rise in net profit for the fourth quarter of FY25. The increase was mainly due to strong growth in its respiratory and vaccine portfolios.

At 10:20 AM, GSK Pharma's share price was up 4.70% and was trading at ₹2,919.90.

Breakdown of GSK Q4 FY25 Earnings Results  

For the quarter ending March 31, 2025, GSK’s net profit rose to ₹262.9 crore, compared to the same period last year. The revenue grew 4.8% year-on-year to ₹974.4 crore.

The company’s EBITDA (earnings before interest, taxes, depreciation, and amortisation) increased 30% to ₹331 crore on a standalone basis. EBITDA margins also improved by 620 basis points to 34%, helped by lower raw material costs, better productivity, and operational efficiency.

Focus on Efficiency 

GSK highlighted that it continues to improve efficiency across its operations. Selling, general and administrative (SG&A) expenses as a percentage of sales fell by 4.2% year-on-year in the quarter. Field productivity improved by 9%, showing better results from the sales team.

Highlights of GSK Q4 FY25 Earnings Results

For the entire FY25, GSK reported:

• Revenue of ₹3,749 crore, up 8.6%
• Net profit of ₹927.6 crore, up 57%
• EBITDA of ₹1,169 crore, up around 30%
• EBITDA margins expanded by 500 basis points to 31%.
• Final dividend of ₹42 per share, compared to ₹32 last year. 

The company's senior management believes that key brands such as Augmentin, Calpol, Ceftum, T-Bact, and Trelegy helped drive business growth. The company’s focus on innovation, doctor engagement, and digital tools also paid off.

Future Plans 

Looking ahead, GSK plans to launch two oncology drugs to strengthen its portfolio of innovative drugs in India:

• Zejula (Niraparib) for ovarian cancer
• Jemperli (Dostarlimab) for endometrial cancer

Conclusion 

GSK Pharmaceuticals India's latest results reflect ongoing developments in the healthcare and pharmaceutical industry. With continued focus on innovation, efficiency, and a diverse product portfolio, the company is aligning itself with evolving market needs. As the industry moves forward, strategic launches and operational improvements are expected to play a key role in shaping future outcomes.

Read more on: Best Pharma Stocks in May 2025: Neuland Labs, Suven Pharma, Laurus Labs and More – Based on 5-Yr CAGR. 
 
Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks. Read all the related documents carefully before investing.